Denosumab 70 mg/mL + Zoledronic acid 4 mg + Placebo IV + Placebo SC
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Fractures, Bone
Conditions
Fractures, Bone
Trial Timeline
Aug 1, 2013 → Apr 1, 2016
NCT ID
NCT01920568About Denosumab 70 mg/mL + Zoledronic acid 4 mg + Placebo IV + Placebo SC
Denosumab 70 mg/mL + Zoledronic acid 4 mg + Placebo IV + Placebo SC is a phase 3 stage product being developed by Amgen for Fractures, Bone. The current trial status is completed. This product is registered under clinical trial identifier NCT01920568. Target conditions include Fractures, Bone.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01920568 | Phase 3 | Completed |
Competing Products
12 competing products in Fractures, Bone
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| VK5211 + Placebo | Viking Therapeutics | Phase 2 | 47 |
| Teriparatide + Placebo | Eli Lilly | Approved | 85 |
| Teriparatide 20 mcg | Eli Lilly | Phase 3 | 77 |
| Zoledronic Acid 5Mg/Bag 100Ml Inj + sodium chloride | Roche | Approved | 85 |
| rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM + rhBMP-2/CPM | Pfizer | Phase 2/3 | 64 |
| rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| InductOs | Pfizer | Approved | 84 |
| rhBMP-2/CPM | Pfizer | Phase 1 | 32 |
| rhBMP-2/CPM + rhBMP-2/CPM | Pfizer | Phase 2 | 51 |
| Tranexamic Acid plus standard of care | Pfizer | Approved | 84 |
| CP-533, 536 + Placebo + CP-533,536 + CP-533,536 + CP-533,536 | Pfizer | Phase 2 | 51 |
| enoxaparin (XRP4563) | Sanofi | Phase 3 | 76 |